Skip to content

Study · Not a test of the peptide alone · 2012

5 results

Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.

Samyshkin Y, Guillermin AL, Best JH, Brunell SC, Lloyd A

Journal of medical economics16 Jul 2012Cited by 29 (Europe PMC)

PMID22793669 (opens in a new tab)DOI10.3111/13696998.2012.708691 (opens in a new tab)PepBankPUB-22793669
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 01Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In a diabetes simulation, once-weekly exenatide increased projected lifetime costs compared with insulin glargine.

    In plain wordsA computer model projected higher lifetime costs with once-weekly exenatide than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseLifetime medical cost
    Study

    n: not reported in source

    CORE Diabetes Model
    Comparator
    insulin glargine
    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    Incremental cost
    3914 USD
    exenatide versus insulin glargine

    Source sentences

    Summary
    Over a lifetime horizon, and compared with IG, EQW was associated with an incremental cost of $3914 (SD = 2923).
    1 context sentence
    Summary · context
    A validated computer simulation model, the CORE Diabetes Model, was used to project lifetime clinical outcomes and direct medical costs.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 02Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In a diabetes simulation, once-weekly exenatide increased projected life expectancy compared with insulin glargine.

    In plain wordsA computer model projected longer life with once-weekly exenatide than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseProjected life expectancy
    Study

    n: not reported in source

    CORE Diabetes Model
    Comparator
    insulin glargine
    Outcome group
    Mortality · Whole body

    Measurements

    Life expectancy gain
    0.135 years
    exenatide versus insulin glargine

    Source sentences

    Summary
    EQW was projected to increase life expectancy by 0.135 (SD = 0.216) years and to improve quality-adjusted life expectancy by 0.246 (SD = 0.147) quality-adjusted life years (QALYs), generating an incremental cost-effectiveness ratio (ICER) of $15,936/QALY.
    1 context sentence
    Summary · context
    A validated computer simulation model, the CORE Diabetes Model, was used to project lifetime clinical outcomes and direct medical costs.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 03Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In a diabetes simulation, once-weekly exenatide increased projected quality-adjusted life expectancy compared with insulin glargine.

    In plain wordsA computer model projected more quality-adjusted life years with once-weekly exenatide than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseQuality-adjusted life expectancy
    Study

    n: not reported in source

    CORE Diabetes Model
    Comparator
    insulin glargine
    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    Quality-adjusted life expectancy gain
    0.246 QALYs
    exenatide versus insulin glargine

    Source sentences

    Summary
    EQW was projected to increase life expectancy by 0.135 (SD = 0.216) years and to improve quality-adjusted life expectancy by 0.246 (SD = 0.147) quality-adjusted life years (QALYs), generating an incremental cost-effectiveness ratio (ICER) of $15,936/QALY.
    1 context sentence
    Summary · context
    A validated computer simulation model, the CORE Diabetes Model, was used to project lifetime clinical outcomes and direct medical costs.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 04Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In a diabetes simulation, once-weekly exenatide had an incremental cost-effectiveness ratio of $15,936/QALY compared with insulin glargine.

    In plain wordsA computer model estimated an extra $15,936 per quality-adjusted life year for once-weekly exenatide compared with insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableIncremental cost-effectiveness ratio
    Study

    n: not reported in source

    CORE Diabetes Model
    Comparator
    insulin glargine
    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    ICER
    15,936 USD/QALY
    exenatide versus insulin glargine

    Source sentences

    Summary
    EQW was projected to increase life expectancy by 0.135 (SD = 0.216) years and to improve quality-adjusted life expectancy by 0.246 (SD = 0.147) quality-adjusted life years (QALYs), generating an incremental cost-effectiveness ratio (ICER) of $15,936/QALY.
    1 context sentence
    Summary · context
    A validated computer simulation model, the CORE Diabetes Model, was used to project lifetime clinical outcomes and direct medical costs.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  5. 05Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In a diabetes simulation, sensitivity analyses supported once-weekly exenatide's cost-effectiveness compared with insulin glargine.

    In plain wordsComputer sensitivity analyses supported once-weekly exenatide's cost-effectiveness compared with insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableCost-effectiveness sensitivity analyses
    Study

    n: not reported in source

    CORE Diabetes Model
    Comparator
    insulin glargine
    Outcome group
    Healthcare costs and utilization · Whole body

    Source sentences

    Summary
    One-way and probabilistic sensitivity analyses confirmed EQW's cost-effective profile.
    2 context sentences
    Summary · context
    Assuming a payer's willingness to pay threshold of $50,000/QALY, EQW is therefore cost-effective compared to IG.
    Summary · context
    A validated computer simulation model, the CORE Diabetes Model, was used to project lifetime clinical outcomes and direct medical costs.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.